Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications
W. Joseph Herring, Thomas Roth, Andrew D. Krystal, et al.
Journal of Sleep Research (2018) Vol. 28, Iss. 2
Closed Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

Clinical trials of new drugs for Alzheimer disease
Li-Kai Huang, Shu-Ping Chao, Chaur‐Jong Hu
Journal of Biomedical Science (2020) Vol. 27, Iss. 1
Open Access | Times Cited: 587
Insomnia disorder: State of the science and challenges for the future
Dieter Riemann, Fee Benz, Raphael J. Dressle, et al.
Journal of Sleep Research (2022) Vol. 31, Iss. 4
Open Access | Times Cited: 191
Hypocretins (orexins): The ultimate translational neuropeptides
Laura H. Jacobson, Daniël Hoyer, Luı́s de Lecea
Journal of Internal Medicine (2022) Vol. 291, Iss. 5, pp. 533-556
Closed Access | Times Cited: 71
The Extraordinary Importance of Sleep: The Detrimental Effects of Inadequate Sleep on Health and Public Safety Drive an Explosion of Sleep Research.
Susan Worley
PubMed (2018) Vol. 43, Iss. 12, pp. 758-763
Closed Access | Times Cited: 156
Neuronal Networks in Hypertension
Patrice G. Guyenet, Ruth L. Stornetta, George M. P. R. Souza, et al.
Hypertension (2020) Vol. 76, Iss. 2, pp. 300-311
Open Access | Times Cited: 74
An update on the novel and approved drugs for Alzheimer disease
Hassan A. Alhazmi, Mohammed Albratty
Saudi Pharmaceutical Journal (2022) Vol. 30, Iss. 12, pp. 1755-1764
Open Access | Times Cited: 65
Sleep Physiology, Circadian Rhythms, Waking Performance and the Development of Sleep-Wake Therapeutics
Derk‐Jan Dijk, Hans‐Peter Landolt
Handbook of experimental pharmacology (2019), pp. 441-481
Open Access | Times Cited: 55
Effects of orexin receptor antagonism on human sleep architecture: A systematic review
Jacob Clark, Maddison L. Brian, Sean P. A. Drummond, et al.
Sleep Medicine Reviews (2020) Vol. 53, pp. 101332-101332
Closed Access | Times Cited: 54
Hypocretin/Orexin Receptor Pharmacology and Sleep Phases
Yu Sun, Ryan K. Tisdale, Thomas S. Kilduff
Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences (2021), pp. 22-37
Open Access | Times Cited: 42
Targeting the orexin/hypocretin system for the treatment of neuropsychiatric and neurodegenerative diseases: From animal to clinical studies
Marc Ten-Blanco, África Flores, Luigia Cristino, et al.
Frontiers in Neuroendocrinology (2023) Vol. 69, pp. 101066-101066
Open Access | Times Cited: 19
Orexin receptor antagonists in the pathophysiology and treatment of sleep disorders and epilepsy
Mohammad Sheibani, Maryam Shayan, Mina Khalilzadeh, et al.
Neuropeptides (2023) Vol. 99, pp. 102335-102335
Closed Access | Times Cited: 18
Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia
Ramón Cacabelos
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 9, pp. 3059-3059
Open Access | Times Cited: 48
Involvement of orexinergic system in psychiatric and neurodegenerative disorders: A scoping review
Hayder M. Al‐kuraishy, MayH Abdulhadi, NawarR Hussien, et al.
Brain Circulation (2020) Vol. 6, Iss. 2, pp. 70-70
Open Access | Times Cited: 46
Sleep–Wake Disorders in Alzheimer’s Disease: A Review
Yu-Ying Sun, Zhun Wang, He-Yan Zhou, et al.
ACS Chemical Neuroscience (2022) Vol. 13, Iss. 10, pp. 1467-1478
Closed Access | Times Cited: 19
Insomnia as a predictor of diagnosed memory problems: 2006–2016 Health and Retirement Study
Hind A. Beydoun, May A. Beydoun, Jordan Weiss, et al.
Sleep Medicine (2021) Vol. 80, pp. 158-166
Open Access | Times Cited: 24
Translational approaches to influence sleep and arousal
Ritchie E. Brown, Tristan J. Spratt, Gary B. Kaplan
Brain Research Bulletin (2022) Vol. 185, pp. 140-161
Open Access | Times Cited: 17
Synthesis and clinical application of new drugs approved by FDA in 2022
Jingyi Zhang, Yatao Wang, Lu Sun, et al.
Molecular Biomedicine (2023) Vol. 4, Iss. 1
Open Access | Times Cited: 9
Sleep therapeutics and neuropsychiatric illness
Andrew D. Krystal
Neuropsychopharmacology (2019) Vol. 45, Iss. 1, pp. 166-175
Open Access | Times Cited: 29
At the intersection of sleep deficiency and opioid use: mechanisms and therapeutic opportunities
Mark K. Greenwald, Tabitha E.H. Moses, Timothy Roehrs
Translational research (2021) Vol. 234, pp. 58-73
Open Access | Times Cited: 20
Daridorexant for the Treatment of Insomnia
Christopher L. Robinson, Rajesh Supra, Evan Downs, et al.
Health psychology research (2022) Vol. 10, Iss. 3
Open Access | Times Cited: 15
Dysregulation of striatal dopamine D2/D3 receptor-mediated by hypocretin induces depressive behaviors in rats
Bing Chen, Jiangang Xu, Simiao Chen, et al.
Journal of Affective Disorders (2023) Vol. 325, pp. 256-263
Closed Access | Times Cited: 8
Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT Analysis
Uta Schilling, Andrea Henrich, Clemens Muehlan, et al.
Clinical Drug Investigation (2021) Vol. 41, Iss. 8, pp. 711-721
Closed Access | Times Cited: 17
The Discovery of Suvorexant: Lessons Learned That Can Be Applied to Other CNS Drug Development Efforts
Jason M. Uslaner, W. Joseph Herring, Paul J. Coleman
ACS Pharmacology & Translational Science (2020) Vol. 3, Iss. 1, pp. 161-168
Open Access | Times Cited: 13
Dual orexin receptor antagonist ameliorates sleep deprivation-induced learning and memory impairment in APP/PS1 mice
Yaran Li, Z. Yan, Na Shao, et al.
Sleep Medicine (2024) Vol. 121, pp. 303-314
Closed Access | Times Cited: 1
Oxadiazole Derivatives as Dual Orexin Receptor Antagonists: Synthesis, Structure–Activity Relationships, and Sleep‐Promoting Properties in Rats
Christine Brotschi, Catherine Roch, John Gatfield, et al.
ChemMedChem (2019) Vol. 14, Iss. 13, pp. 1257-1270
Closed Access | Times Cited: 10
Page 1 - Next Page

Scroll to top